New lab facility for Shanbally

A €60 million investment has been announced by a biotechnology company as part of an expansion to its facility in Shanbally.

BioMarin Pharmaceutical Inc said its new laboratory facility will allow the company to increase production capacity for currently approved medicines and create room for future growth.

The company, which employs more than 500 people in Ireland, operates a manufacturing site in Shanbally and a commercial office in Dublin.

Evelyn Marchany Garcia, Senior Vice President, Chief Quality Officer, BioMarin Pharmaceutical, said: “This investment in our Cork facility reflects our ongoing commitment to enhancing our industry-leading global manufacturing capabilities and supporting the growth of our innovative medicines for our people living with rare conditions around the world.”

Michael Lohan, CEO, IDA Ireland said: “By opening this new quality control and process development laboratory, BioMarin will create new opportunities for collaboration, talent development and growth, ensuring that the life sciences sector in Ireland continues to make an impact on patients’ lives worldwide.”

The facility in Shanbally is BioMarin’s only manufacturing site outside of the United States.

Conor Delaney, Site Lead and Vice President of Shanbally Manufacturing Operations, BioMarin Pharmaceutical said: “Expanding our laboratories allows us to deliver our medicines more efficiently and at greater scale for people living with genetic conditions. This latest investment reinforces our commitment to advancing treatment options and supporting patients across the world.”